OncoMatch/Clinical Trials/NCT06575127
Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study
Is NCT06575127 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies FOLFOXIRI Protocol for neoplasm malignant.
Treatment: FOLFOXIRI Protocol — This prospective Phase II study aims to evaluate the efficacy and safety of a modified FOLFOXIRI regimen in the treatment of metastatic colorectal cancer (MCRC). FOLFOXIRI, though effective, is known for its high toxicity, necessitating close monitoring and dose adjustments. . The primary endpoint is to assess the impact on the objective response rate and evaluate both acute and delayed toxicity. The secondary endpoints include studying the treatment's effectiveness as conversion therapy, along with disease-free survival (DFS) and overall survival (OS). The tertiary endpoint focuses on evaluating predictive and prognostic factors of significance. This study seeks to balance the efficacy of FOLFOXIRI with a modified dose to minimize toxicity while maintaining therapeutic benefits, providing a potentially safer and effective option for patients with MCRC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Excluded: DPYD mutation
Disease stage
Required: Stage UNRESPECTABLE, IV
Metastatic disease required
Histologically confirmed unrespectable or metastatic colorectal cancer with or without primary tumor in situ.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: adjuvant/neoadjuvant therapy not in metastatic setting
Prior exposure to chemotherapy treatment for colorectal cancer in the metastatic setting
Lab requirements
Blood counts
adequate baseline hematology
Cardiac function
adequate cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify